NMR Characteristics and Crystal Structure of Cytarabine HepDirect Prodrug MB07133

  • WANG Ming ,
  • WANG Min-chang* ,
  • ZHAO Xiao-jing ,
  • SU Peng-fei ,
  • PAN Qing ,
  • CHEN Zhi-qun ,
  • LI Xiao-yu
Expand
  • Xi´an Modern Chemistry Research Institute, Xi´an 710065, China
*Corresponding author:WANG Min-chang, Tel: +86-029-88291664, E-mail: wmc204@163.com

Received date: 2014-08-27

  Revised date: 2015-07-24

  Online published: 2015-09-05

Abstract

The structure of the title compound (MB07133) was determined by one-dimensional (i.e., 1H and 13C NMR) and two-dimensional (i.e., 1H-1H COSY, gHSQC and gHMBC) NMR techniques. The 1H and 13C NMR chemical shifts were assigned. The crystal structure of the compound was determined using X-ray single crystal diffraction. The spectral feature and crystal structure of the compound, as well as the structure-function relationship with respective to its use as a prodrug, were discussed.

Cite this article

WANG Ming , WANG Min-chang* , ZHAO Xiao-jing , SU Peng-fei , PAN Qing , CHEN Zhi-qun , LI Xiao-yu . NMR Characteristics and Crystal Structure of Cytarabine HepDirect Prodrug MB07133[J]. Chinese Journal of Magnetic Resonance, 2015 , 32(3) : 518 -527 . DOI: 10.11938/cjmr20150313

References

[1]  Boyer, Serge H, Sun Z L,  et al. Gomez D arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma[J]. J Med Chem, 2006, 49(26): 7 711-7 720.

[2]  Hecker S J, Erion M D. Prodrugs of phosphates and phosphonates[J]. J Med Chem, 2008, 51: 2 328-2 345.

[3]  MacKenna, Deidre A, Montag,  et al. Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma[J]. Cancer Chemoth Pharm, 2009, 64(5): 981-991.

[4]  Erion Mark D, Van Poelje, Paul D,  et al. Liver-targeted drug delivery using HepDirect prodrugs[J]. J Pharm Exp Ther, 2005, 312(2): 554-560.

[5]  Schultz C. Prodrugs of biologically active phosphate esters[J]. Bioorg Med Chem, 2003, 11: 885-898.

[6]  Krise J P, Stella V J. Prodrugs of phosphates, phosphonates, and phosphinates[J]. Adv Drug Deliv-Rev, 1996, 19: 287-310.

[7]  Sofia M J, Bao D, Chang W,  et al. Discovery of a  β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug(PSI-7977) for the treatment of hepatitis C virus[J]. J Med Chem, 2010, 53: 7 202-7 218.

[8]  Dang Q, Kasibhatla S R, Jiang T, et al. Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors[J]. J Med Chem, 2008, 51: 4 331-4 339.

[9]  Siddiqui A Q, McGuigan C, Ballatore C,  et al. Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR[J]. J Med Chem, 1999, 42: 4 122-4 128.

[10]  Zhu Z J, Chen H G, Goel O P, et al. Phosphate prodrugs of PD154075[J]. Bioorg Med Chem Lett, 2000, 10: 1 121-1 124.

[11]  Chen Yue(陈玥), Li Jian-feng(李剑峰), Wei Ya-bing(韦亚兵),  et al. Spectral data deduced structure of new drug lomerizine dihydrochloride(新药盐酸洛美利嗪的波谱特征与结构确证)[J]. Chinese J Magn Reson(波谱学杂志), 2006, 23(3): 341-348.

[12]  Zhang Pei-xuan(张佩璇), Li Jian-feng(李剑峰), Wei Ya-bing(韦亚兵),  et al. NMR characterization and structural elucidation of fluorine derivative of tetrahydroberberine(氟代四氢小檗碱的波谱特征与结构解析)[J]. Chinese J Magn Reson(波谱学杂志), 2009, 26(1): 111-119.

[13]  Erion M D, Reddy K R, Boyer S H,  et al. Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver[J]. J Am Chem Soc, 2004, 126: 5 154-5 163.

[14]  Moosavi-Movahedi A A, Hakimelahi S, Chamani J,  et al. Design, synthesis, and anticancer activity of phosphonic acid diphosphate derivative of adenine-containing butenolide and its water-soluble derivatives of paclitaxel with high antitumor activity[J]. Bioorg Med Chem, 2003, 11: 4 303-4 313.

[15]  Erion M D, Van Poelje, Mackenna D A, et al. L iver-targeted drug delivery us ing hepDirect prodrugs[J]. J Pharm Exp Ther, 2005, 312(2): 554-560.

[16]  Boyer S H, Sun Z, Jiang H J,  et al. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma[J]. J Med Chem, 2006, 49(26): 7 711-7 720.

Outlines

/